Bessemer Group’s Arcutis Biotherapeutics ARQT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5K Hold
190
– – ﹤0.01% 2270
2026
Q2
$5K Hold
190
– – ﹤0.01% 2263
2026
Q1
$4K Buy
190
+52
+38% +$1.33K ﹤0.01% 2249
2025
Q4
$4K Hold
138
– – ﹤0.01% 2276
2025
Q3
$3K Buy
+138
New +$2.18K ﹤0.01% 2219
2024
Q4
– Sell
-110
Closed -$1K – 2456
2024
Q3
$1K Sell
110
-250
-69% -$2.47K ﹤0.01% 2327
2024
Q2
$3K Buy
+360
New +$3.26K ﹤0.01% 1808

Other funds holding ARQT

Bessemer Group's ARQT Position: Q3 2026 in Review

Bessemer Group held its Arcutis Biotherapeutics (ARQT) position steady in Q3 2026 at 190 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #2270.

Bessemer Group first reported a position in ARQT in Q2 2024 and has held it in 7 quarters since. 294 funds tracked by Wall St. Rank hold ARQT as of Q3 2026.

  • Bessemer Group held 190 shares of Arcutis Biotherapeutics worth $5K as of Q3 2026.
  • Bessemer Group left its Arcutis Biotherapeutics share count unchanged in Q3 2026.
  • Arcutis Biotherapeutics made up ﹤0.01% of Bessemer Group's portfolio in Q3 2026, its #2270 holding.
  • Bessemer Group first reported a position in Arcutis Biotherapeutics in Q2 2024 and has held it in 7 quarters since.
  • 294 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2026.

Based on Bessemer Group's 13F filing for Q3 2026, filed 9 Nov 2026.